WAT — Waters Corporation

The tape and the sell-side agree on direction, if not enthusiasm. On August 4, 2026 Waters reported Q2 2026 revenue of $1.645B (above the high end of guidance), +7% organic (+9% constant currency), with adjusted EPS of $3.05 at the high end despite FX headwinds; management raised full-year 2026 guidance. ASD posted 8% instrument growth and double-digit chemistry consumables growth on a pharma and academic/government recovery, and the newly acquired BDS business grew 4% comparable, beating expectations under the '180-day growth revitalization plan.' The late-July 2026 Xevo TQ Absolute XR IVD launch added a clinical diagnostics catalyst. Analyst consensus is Buy (19 buy, 16 hold, 2 sell) with a consensus target of $438.36 and a $387-$490 range. As of 2026-09-13 that bullishness is already partly in the price: +42.5% over six months, RSI 52.9, and the stock sitting just 4% under its 52-week high.

Pre-acquisition, Waters was a steady mid-single-digit compounder, not a hypergrowth story: quarterly revenue rose from $711.7M in Q3 2023 to $932.4M in Q4 2025, with YoY growth of +4.0% (Q3 2024), +6.5% (Q4 2024), +3.9% (Q1 2025), +8.9% (Q2 2025), +8.1% (Q3 2025) and +6.8% (Q4 2025) — a mild acceleration through 2025, consistent with the brief's 'broader market recovery' language. The BDS deal creates a hard structural break at Q1 2026: revenue jumps to $1,267M (+91% YoY) and then $1,645M in Q2 2026 (+113% YoY), while reported operating income turns negative (-$47M and -$86M) and gross margin collapses from 58.3% in Q2 2025 to 44.6% in Q2 2026. That is purchase accounting and step-up charges, not a demand problem — management still delivered $3.05 adjusted EPS in Q2 2026. TTM figures (operating margin 8.0%, net margin 3.6%, EPS $1.692) are therefore meaningless. The single most important trend to watch is whether GAAP gross margin claws back toward the high-50s over the next two to three quarters; if it does not, the dilution is structural and consensus FY2027 EPS of $14.573 is too high.

Fair — and cheaper than the deterministic model's 'Rich vs. its own history' label implies, because that label is built on trailing data that is currently garbage. As of 2026-09-13, the TTM P/E of 101.6x and PEG of -1.59 are artifacts of acquisition-distorted TTM EPS of $1.692, and the 2.64x price/book is misleadingly low only because book equity ballooned with shares issued for the deal. On forward numbers the picture inverts: at $408.34 the stock is 28.0x FY2027 consensus EPS of $14.573 and ~4.7x FY2027 revenue of $6.455B, versus a 5-year average P/E of 32.42x and average P/S of 7.26x. Even granting a legitimate haircut for $4.9B of long-term debt and integration risk, that is a mid-teens discount to its own historical multiple. Not cheap in absolute terms for ~10% EPS growth, but not expensive either.

Because GAAP EPS is negative in both Q1 and Q2 2026, the entire $408.34 price is a wager on adjusted earnings that have not yet appeared in reported results — the market is pricing in a turnaround that is only visible in non-GAAP numbers and management commentary. At 28.0x FY2027E EPS, the market is paying a premium multiple on roughly 10% EPS growth (FY2026E ~$13.2 to FY2027E $14.573), which only clears if BDS synergies land and pharma/A&G spending keeps recovering. If organic growth settles back to 3-5% and the gross-margin recovery stalls, a 23-25x multiple on $14.00-$14.50 gets you $325-$360; that is the real downside on an earnings miss. If GAAP gross margin returns to the mid-50s and adjusted EPS clears $15.50, 30-32x supports $465-$495. Read the GAAP gross margin line and BDS comparable growth, not the headline adjusted beat.

Neutral-to-constructive, but not an entry signal. As of 2026-09-13, RSI(14) was 52.9 — dead center, with no overbought or oversold read. At $408.34 the stock sat -0.4% versus its 20-day SMA (~$410), +3.6% versus its 50-day (~$394) and +13.0% versus its 200-day (~$361): a clean, intact uptrend that has flattened over the past month (-1.9% one-month, -0.3% one-week) after +14.9% over three months and +42.5% over six. With the stock 4% below its 52-week high of $426.22, there is no momentum-of-valuation cushion. Timing implication: the 50-day near $394, or the $380-$390 shelf, is a materially better add zone than chasing $408; a decisive close below the 50-day would signal the post-earnings drift is finished.

• Life-science instrument capex is in the post-inventory-digestion recovery phase, with pharmaceutical R&D and academic & government budgets re-accelerating — this is the engine behind the +7% organic (+9% cc) growth reported for Q2 2026.
• China policy risk: DRG-based healthcare reimbursement changes and export constraints continue to pressure instrument sales into Asia, a recurring quarterly-swing factor for the entire analytical tools sector.
• FX translation remains a modest headwind from a strong dollar, partly offsetting constant-currency strength — management called out FX explicitly alongside the Q2 2026 adjusted EPS result.
• Rate sensitivity is now structurally higher: after the BDS deal Waters carries $4.886B of long-term debt against only $539M of cash, so refinancing costs and the pace of deleveraging matter to equity value in a way they did not pre-acquisition.
• Sector rotation into defensive healthcare/med-tech has supported the multiple, and analytical instruments with recurring consumables revenue typically attract premium multiples in that rotation — supportive, but it also means any growth scare unwinds the re-rating quickly.

• Q3 2026 earnings on November 3, 2026 — the first real test of whether the raised FY2026 guidance tracks to the upper end and whether GAAP gross margin recovers as purchase-accounting charges roll off.
• Evidence on the BDS '180-day growth revitalization plan' and disclosed synergy capture; BDS comparable growth of 4% in Q2 2026 needs to close the gap with ASD's 8% instrument growth.
• Sustained pharma and academic/government order recovery — the swing factor behind whether organic growth holds at 7-9% or fades to the low single digits.
• New product cadence, including the late-July 2026 Xevo TQ Absolute XR IVD clinical mass spectrometer launch, which expands the higher-margin diagnostics footprint.
• Deleveraging on the $4.886B long-term debt — faster paydown would support multiple expansion and/or buybacks, and is one of the few levers management controls outright.

• The GAAP-versus-adjusted gap: Q2 2026 gross margin of 44.6% versus 58.3% a year earlier, with negative operating income. If that reflects structural mix dilution from BDS rather than one-time purchase accounting, the FY2027 consensus EPS of $14.573 is materially too high.
• Leverage: $4.886B of long-term debt against $539M of cash, a debt load with no precedent in this company's history. The reported 0.346 debt-to-equity ratio understates it because equity was inflated by shares issued for the deal.
• No trailing-earnings cushion — TTM EPS of $1.692 and a 101.6x TTM P/E mean the stock is priced entirely on adjusted estimates, after a 42.5% six-month run that leaves little room for an execution stumble.
• Asia-Pacific policy and export restrictions plus FX can cap reported growth even when Western demand is healthy, and the deterministic score's own notes flag that trend comparisons spanning Q1 2026 are distorted.
• Integration risk: the reported growth rate is acquisition scale, not organic momentum, and the market may be extrapolating the former as the latter — BDS growing 4% comparable is roughly half the ASD instrument growth rate.

A high-quality analytical instrument franchise temporarily wearing ugly GAAP numbers. The BDS deal roughly doubled revenue but wrecked the reported income statement (Q2 2026 operating margin of -5.2%, gross margin down ~1,370bps YoY), while $3.05 adjusted EPS and +7-9% organic growth show a business that is actually functioning. At $408.34 and 28.0x FY2027E EPS versus a 5-year average of 32.4x, you are not overpaying for the recovery — but you are paying up for a story that still has to prove its margin math in reported results, against $4.9B of new debt and real China headwinds. Constructive, not a bargain; better accumulated on a pullback toward the 50-day (~$394) than chased at 4% off the 52-week high.

Blended forward-multiple approach as of 2026-09-13: 29x FY2027 consensus EPS of $14.573 (a ~10% haircut to Waters' 5-year average P/E of 32.42x for integration and balance-sheet risk) implies ~$423, cross-checked against 17.5x FY2027E EBITDA of ~$2.1B on a ~$34.9B enterprise value (market cap $30.5B plus net debt ~$4.35B), which implies ~$433; averaging the two methods yields ~$428.